MedTrace Logo

Observational Study on Characteristics and Survival Correlates of Progressive Multifocal Leukoencephalopathy (PML) in Italy

NCT06594614 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 456

Last updated 2024-09-19

No results posted yet for this study

Summary

The goal of this observational study is to learn about the features of Progressive Multifocal Leukoencephalopathy (PML) at the time of its diagnosis and the factors that may influence the outcome of persons with this disease.

PML is a rare and rapidly progressive disease of the brain, caused by a virus named JC polyomavirus (JCV). This disease almost always occurs in persons with an immune dysfunction. In some people, the underlying immune dysfunction may be the consequence of other conditions, such as certain hematological tumors (for instance, some lymphomas) or the infection with the Human Immune Deficiency Virus (HIV). In other cases it may be associated with other forms of immune deficiency, either present at birth or acquired later in life, or with immunosuppressive or immunomodulant treatments, such as Natalizumab in persons with Multiple Sclerosis.

Unfortunately, there is no cure for PML, and the only possibility to stop the progression of the disease is to eliminate the cause of the underlying immune dysfunction. This is not always possible, or it may take time, and, therefore, more than half of the persons who developed PML will not survive to the disease.

This study takes advantage of the systematic collection, over a time frame of 37 years, of the characteristics of 456 cases of PML. The main question of this study aims to answer whether and how PML characteristics and outcome have evolved over time and also according to the disease or condition that caused the immune dysfunction leading to PML.

This is important because PML is a rare disease, and, therefore, knowing the context in which it develops can be useful for healthcare providers and families to consider PML as a possible cause of unexpected neurological problems. In fact, an early recognition of PML is associated with a better outcome. On the other hand, there are clinical and laboratory features of PML that can also be associated with different disease outcome. Therefore, it is important that these features are identified, to provide important information for disease management and also for the design of experimental therapeutic interventions.

Participants of this study are persons with a diagnosis of PML who were followed at the Infectious Diseases Unit of San Raffaele Hospital in Milan or referred to the Unit from other Italian clinical centers, between January 1st 1987 and April 30th 2024. We have retrospectively reviewed their clinical charts and collected demographic characteristics, together with the clinical, radiological and laboratory features of PML at the time of its diagnosis. In addition we have also reviewed the evolution of the disease one-year after the date of diagnosis.

The data from the participants have been collected in a custom-made database, which is kept updated with follow-up data and inclusion of new participants. As by April 30th 2024, 456 participants have been included in the database. This is one of the largest existing cohorts and the one with the longest observational window. In addition, and differently from previous cohort studies, it analyzes in detail clinical, radiological, and virological characteristics of PML, providing additional information on their changes over time and possible predictors of disease outcome.

Conditions

  • Progressive Multifocal Leukoencephalopathy
  • PML

Sponsors & Collaborators

  • Scientific Institute San Raffaele

    lead OTHER

Principal Investigators

  • Paola Cinque, MD, PhD · San Raffaele Scientific institute

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1987-01-01
Primary Completion
2024-04-30
Completion
2024-04-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06594614 on ClinicalTrials.gov